June 7th 2024
WINNCARE ACQUIRES PHARMAOUEST
Specialist in Medical Beds and Anti-Bedsore Mattresses, Winncare Announces the Acquisition of Pharmaouest Industries at the End of 2021
June 7th 2024
Specialist in Medical Beds and Anti-Bedsore Mattresses, Winncare Announces the Acquisition of Pharmaouest Industries at the End of 2021
Pharmaouest Industries employs 250 people, including 130 at Miniac-Morvan, and generates a turnover of €28 million, with 60% coming from pressure ulcer prevention devices (mattresses, cushions for chairs or wheelchairs). The SME is particularly noted for its “recognized expertise in the manufacture of viscoelastic foam products.” Its products are manufactured at its Breton site and in Tunisia, where Pharmaouest has a second production site employing about 100 people. At the beginning of the year, the company launched an extension of its Miniac-Morvan site to support growth and relocate part of its production, particularly dynamic (air) mattresses for pressure ulcer prevention, which it currently purchases from China. The project represents an investment of over €2 million, including machinery.
“This acquisition allows Winncare to expand its range of products and services dedicated to pressure ulcer management for healthcare providers and institutions,” it was noted. The new group’s consolidated revenue is expected to reach €115 million by March 2022 globally, with three production sites in France (two for Winncare and one for Pharmaouest Industries) and a presence in Poland, Spain, Tunisia, the United Kingdom, and the Scandinavian countries. This merger represents the first external growth operation carried out by Winncare following the entry of Siparex ETI as the majority shareholder.
“With a foundation strengthened by this acquisition, the Winncare Group has solid assets to continue this strategy beyond our borders, where it already generates nearly 50% of its activity,” said Alexandre Tremblin, partner at Siparex ETI. The operation is supported by Nathalie and Frédéric Mittre, founders of Pharmaouest Industries, who are reinvesting alongside Siparex.